Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials

DOI10.1214/16-AOAS982MaRDI QIDQ512445zbMATH OpenFDO

Authors Ruitao Lin, Guosheng Yin

Publication date 24 February 2017

Published in The Annals of Applied Statistics (Search for Journal in Brave)

zbMATH Keywords

dimension reductionBayesian model averagingmaximum tolerated dosebaggingdrug combination

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10)

Recommendations

• Bayesian dose finding for combined drugs with discrete and continuous doses
• A Bayesian dose-finding design for drug combination trials with delayed toxicities
• A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
• Bayesian phase I/II adaptively randomized oncology trials with combined drugs
• Bayesian Model Averaging Continual Reassessment Method in Phase I Clinical Trials

Cited in

(4)

• Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
• Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
• A nonparametric Bayesian method for dose finding in drug combinations cancer trials
• Novel Bayesian Adaptive Designs and Their Applications in Cancer Clinical Trials

This page was built for publication: Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q512445)